Search This Blog

Monday, September 17, 2018

Piper Jaffray Upgrades Acceleron Pharma (XLRN) to Overweight


Piper Jaffray analyst Danielle Brill upgraded Acceleron Pharma (NASDAQ: XLRN) from Neutral to Overweight with a price target of $75.00 (from $52.00).
The analyst says the Luspatercept opportunity has been de-risked and likes the equity noting the royalty stream remains under-appreciated.

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)